FDA Approves Multiple New Indications for the Brain PET Imaging Agent Vizamyl
Expanded indications for the flutemetamol F18 injection include amyloid quantification and monitoring of anti-amyloid treatments.
The Food and Drug Administration (FDA) has approved multiple new indications for use of the flutemetamol F18 injection in brain positron emission tomography (PET) imaging.
The new indications for flutemetamol F18 injection (Vizamyl, GE HealthCare) include amyloid quantification, monitoring of anti-amyloid therapies, predicting dementia and other cognitive decline due to Alzheimer’s disease (AD), and diagnosing AD, according to GE HealthCare, the manufacturer of Vizamyl.
Here one can see a brain PET scan showing the combination of flutemetamol F18 with amyloid quantification software. (Image courtesy of GE HealthCare.)
While flutemetamol F18 injection was previously approved in 2013 for visual estimation of amyloid neuritic plaque density in adults with cognitive impairment, GE HealthCare said the indication for amyloid quantification facilitates a more objective assessment that goes hand in hand with the new indication for monitoring the effectiveness of anti-amyloid modalities.
“The use of quantification in amyloid PET imaging has steadily moved from research to clinical practice, where it can aid in more confident and accurate diagnosis,” noted Phillip Kuo, M.D., Ph.D, FACR, a professor of radiology, section chief of nuclear medicine and director of theranostics at the City of Hope National Medical Center in Duarte, Calif. “Now quantification can also play a critical role in initiating and monitoring amyloid-targeted therapy for Alzheimer's disease and determining when it can be discontinued.”
GE HealthCare noted that updated criteria from the Alzheimer’s Association in support of AD diagnosis based on an abnormal amyloid PET findings facilitated the AD diagnosis indication for flutemetamol F18 injection.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
